Answers are grounded in this paper and cite their sources.
Our previous studies reported that Qianliening capsule (QC) has a significant therapeutic effect on BPH. Therefore, we investigated the effect QC on apoptosis of human prostatic hyperplasia epithelial-1 cells (BPH-1). The BPH-1 cells were treated with various concentrations of QC in vitro. Morphology of BPH-1 cell was observed, and the cell viability was determined by the 3-(4,5)-dimethylthiahiazo (-z-y1)-3,5-di-phenytetrazoliumromide (MTT) assay. The levels of Cytochrome C, caspase-9 and caspase-3 were detected using the flow cytometry and colorimetric assay respectively. The Bax mRNA and the miRNA-221, -222, -15a, -16, -181a was determine by Real-time PCR analysis. The apoptosis of BPH-1 cells treated with QC increased than that of untreated cells, as evidenced by loss of plasma membrane asymmetry, the nuclear condensation and fragmentation, collapse of mitochondrial membrane potential in a dose depended manner. The levels of Cytochrome C and caspase-9, caspase-3 in the cells treated with QC increased using the flow cytometry and colorimetric assay respectively. The mRNA and protein expression of Bax and the expression of miRNA-181a in the cells treated with QC increased in a dose dependent manner. QC could induce BPH-1 cells apoptosis by regulating miRNA-181a mediated mitochondrial dependent apoptosis pathway, which may be one of the important mechanisms that QC treated benign prostatic hyperplasia.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: